Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome
– Clinical stage biopharmaceutical company completes upsized, oversubscribed Series D financing from leading life sciences investors – CHICAGO—November 3, 2022 – Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clinical trial … Read more